聚乙二醇化重组人粒细胞刺激因子及其药品通用名称命名  

PEGylated Recombinant Human Granulocyte Colony- Stimulating Factor and Nomenclature

作　　者：任跃明[1] 

机构地区：[1]国家药典委员会,北京100061

出　　处：《生物技术通讯》2014年第4期601-604,共4页Letters in Biotechnology

摘　　要：有越来越多的聚乙二醇修饰人粒细胞刺激因子研发上市。为适应这类制品的发展,中国药品通用名命名原则也需要不断更新修订。简要介绍了聚乙二醇修饰蛋白技术以及WHO国际非专利药品名(INN)命名委员会对这类制品的命名情况,讨论了我国对这类制品的药品通用命名原则和方法,建议对聚乙二醇化不同的修饰形式在名称上适当加以区分,并注意加强与INN命名委员会的交流合作。A lot of PEGylated granulocyte colony-stimulating factor have been approved. Therefore, the naming scheme of Chinese Approved Drug Name must be revised to adapting the development of PEGylated protein. In the article, author introduced the PEGylation technology and International Nonproprietary Names（INN） for this prod-ucts. The nomenclature for PEGylated protein in China was discussed. In ＂pegfilgrastim＂, ＂empegfilgrastim＂ and ＂li-pegfilgrastim＂ being assigned by INN expert committee, ＂em＂ and ＂li＂ are the identifiers to distinguish the PE-Gylation. The author proposed that proper identifiers would be added to Chinese Approved Drug Name of different PEGylation protein. In addition, the communication with INN committee should be strengthened.

关 键 词：国际非专利名称 中国药品通用名称 词干 聚乙二醇修饰 重组人粒细胞刺激因子 

分 类 号：R92[医药卫生—药学]